JNJ Company Profile and Key Details

Johnson & Johnson (NYSE:JNJ) closed at $263.04 USD, gaining $9.06 (3.57%) from the previous close of $253.98. The stock is currently trading near its 52-week high $154.21 and $263.10. With a market capitalization of about $633.20 billion, Johnson & Johnson is classified as a mega-cap and shows lower-than-market volatility (beta ~0.23). Key stats such as the average daily volume over the past year has been around 8.14 million shares, in line with its 52-week average. Headquartered in New Brunswick, NJ, Johnson & Johnson operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Joaquin Duato, the company employs approximately 141,700 people and listed since January 02, 1962. Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field.

JNJ has shown sold momentum, gaining 4.05% over the past week and 12.93% over the past quarter, though year-to-date performance is up 5.44%. Short-term trend indicators are bearishly aligned (SMA20 1.56%, SMA50 9.13%, SMA200 29.93%). The stock’s 14-day RSI is 66.51 (firm momentum), while the ATR of 3.71 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -1.52% below its high and over 72.08% above its low. Average 10-day trading volume of 9.17 million shares is slightly above the 3-month average of 7.94 million, indicating heightened recent market interest.

Johnson & Johnson trades at a P/E ratio of 30.34, slightly below the S&P 500 average, with a price-to-sales ratio of 6.57 and a price-to-book ratio of 7.92 trading at moderately above to book value. The P/FCF stands at 35.58, also above market averages.

Johnson & Johnson last paid a dividend of 5.24 per share, this equals a trailing yield of roughly 3.09%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $294.39. This means the shares are trading below this model’s fair value.

Johnson & Johnson generated EPS of $11.05 over the past year. Five-year average earnings growth is 14.9%. Wall Street analysts project EPS growth of 8.28% annually over the next five years. The latest quarter delivered EPS of $2.70. The next quarter is forecast at $2.69. Next year's EPS is expected at $7.19. Analyst sentiment is neutral. Analyst rating data shows there are 12 Strong Buy ratings, 17 Buy ratings, 26 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $280.00 to $167.00. The high target offers 6.45% upside. The low target suggests -36.51% downside. The mean target is $221.24. This offers -15.89% upside. Johnson & Johnson earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 14, 2026, missed forecasts by 0.75%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 2.51% in January 22, 2025.

Johnson & Johnson has 2.41 billion shares outstanding. The public float is 2.40 billion shares, elevated short interest at 0.71% of float. This equals 17.14 million shares. The short ratio is 2.0 days. Institutional investors hold 75.86% of the float. Insiders own 0.06%. Taubert Jennifer L holds 178.01 thousand shares, Wengel Kathryn E has 114.29 thousand shares and Fasolo Peter has 102.70 thousand shares. Over the past six months, insider transactions show net selling. They sold 149.33 thousand shares across 10 transactions.

Our AI price prediction model suggests that Johnson & Johnson stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.82%, with price expected at $288.87 by July 16, 2026, within a range of $283.06 to $294.46 3-Month Outlook: Projected rise of 63.52%, reaching $430.12 by September 30, 2026, with a range of $416.77 to $446.37. 1-Year Outlook: Projected gain of 5.21%, with price at $276.74 by July 02, 2027, within a range of $268.81 to $283.50.

Johnson & Johnson (NYSE:JNJ) shares are flat 5.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Johnson & Johnson trading at a premium to the broader market with a P/E of 30.34. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $193.99, suggesting -26.25% downside. Our AI forecast model points to short-term strength (9.82% over two weeks), a medium-term rise (63.52% over three months), and a longer-term gain (5.21% over one year), with expected trading ranges indicating moderate volatility.